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Abstract
BACKGROUND: There is a clinical need for therapeutic alternative in patients with persisting painful arthritis of AC-joint and 
failure of previous treatments. However, no radiopharmaceutical is currently explicitly approved for radiosynoviorthesis of 
acromioclavicular joint. The aim of our study was to prospectively assess the efficacy and safety of radiosynoviorthesis of 
acromioclavicular joint using erbium-169 citrate.
MATERIAL AND METHODS: Radiosynoviorthesis of acromioclavicular joint was performed in 51 consecutive patients (18 males, 
33 females) mean age 64.3 (range 43.8–82.6, median 63.6) years with clinically confirmed arthritis of 85 acromioclavicular 
joints. The efficacy of RSO was reported by patients according to 10-step visual analogue scale of pain (VAS) (0 = no pain, 
10 = most severe pain) at 6 months after radiosynoviorthesis and by ranking the global therapeutic effect of RSO in 4 categories 
(1 = the best effect, 4 = no change). To assess the variation of blood perfusion in treated joints, the efficacy of RSO was also 
evaluated by variation of target (acromioclavicular joint)/non-target (soft tissue) uptake ratio (T/NTR) of metylendiphosphonate 
(99mTc) measured as number of counts over region of interest on blood pool phase of two-phase bone scintigraphy performed 
before and 6 months after RSO. 
RESULTS: Radiosynoviorthesis was followed by significant decrease in VAS, mean — 3.1 (-47%). Excellent, good, moderate and 
bad response was observed in 57 (67%), 25 (29%), 1 (1%) and in 2 (2%) of acromioclavicular joints respectively. A significant 
correlation between decrease of T/NTR and variation of VAS in % (ρ = 0.532, p < 0.0001) and between T/NTR and subjective 
evaluation of therapeutic effect in scale 1–4 (ρ = 0.388, p = 0.0002) was observed. However, it was not possible to identify 
the cut-off value of relative decrease in T/NTR showing sufficient sensitivity and specificity to detect the therapeutic response. 
CONCLUSION: Results of this prospective study permit to conclude a good efficacy and safety of radiosynoviorthesis using 
erbium-169 citrate in a series of patients with arthritis of acromioclavicular joint in whom previous line(s) of treatment did not 
lead to satisfactory pain relief. 
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Introduction
Acromioclavicular joint (AC-joint) as a part of the shoulder 
girdle complex permits in conjunction with the sternoclavicular joint 
the clavicular rotation and gliding into antero-posterior direction. 
These two articulations represent the only articulation between the 
shoulder girdle, the upper extremities and the trunk. During normal 
activities of daily living the AC-joint experiences significant loading 
on small surface and is frequently subjected to trauma as well. 
Furthermore, as other synovial articulations, AC-joint can be 
involved in rheumatoid arthritis and the seronegative arthropathies. 
In case of persisting seropositive or seronegative arthritis despite 
previous treatments including intraarticular administration of 
corticosteroids, surgical, chemical or radiation synovectomy of 
inflamed hypertrophic synovial membrane can be proposed. To 
avoid surgical synovectomy, several drugs were proposed for 
chemical synovectomy, e.g. rifampicin [1] or osmium acid [2]. The 
main drawback of the chemical synovectomy is its painfulness and 
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relatively low long-term response rate [2]. The bibliographic data 
support the intraarticular administration of appropriate β- emitting 
therapeutic radiopharmaceutical (RSO) as the simple, mini-invasive 
and effective therapeutic option performed in out-patients for the 
local treatment of arthritis, without need for anaesthesia or long 
rehabilitation [3–5]. The low tissue penetration of β- particles up to 
10 mm minimizes the radiation absorbed dose to non-target tissue. 
The absorbed dose of radiation about 100 Gy leads to a synovec-
tomy similar to surgical synovectomy [6]. The leakage rate is low, 
if the joint is immobilized and if particles with an appropriate size of 
5–10 μm are used [5, 7, 8]. The pain reduction typically occurs up to 
4 weeks after RSO. In approximately 3 months the radiation leads to 
reducing of effusion, an inflammatory process and a fibrosis of sy-
novia. If necessary, the procedure can be repeated, but not earlier 
than 6 months after previous RSO; two failed RSOs should not be 
followed by subsequent one [5]. 
According to the guideline of the European Association of 
Nuclear Medicine, candidates for RSO should have been under 
a six-month systemic treatment without encouraging results or 
should have undergone at least one unsuccessful intra-articular 
injection of a long acting glucocorticoid [5]. However, earlier in the 
course of the disease the RSO is indicated, the better results can 
be expected [8].
Several radiopharmaceuticals are currently approved in several 
European countries for RSO: yttrium-90 for knee, rhenium-186 
for medium joints (e.g. ankle, shoulder, elbow, and wrist) and er-
bium-169 for small joints (e.g. fingers, metacarpophalangeal and 
metatarsophalangeal joints). Radionuclides with higher energy of 
β- particles and longer soft tissue range (90Y, 186Re) are used for 
RSO of large/medium articulations and the radionuclides with lower 
energy of β- particles and shorter soft tissue range (169Er) are used 
for RSO of small articulations.
No radiopharmaceutical is currently explicitly approved for RSO 
of AC-joint. However, there is an unmet clinical need for therapeutic 
alternative in patients with persisting painful arthritis of AC-joint and 
failure of previous treatment(s).
The documented efficacy of RSO in significant proportion of 
patients (average response 73 ± 17%) [8] with persistent chronic 
arthritis despite previous line(s) of treatment including intraarticular 
administration of corticosteroids encouraged us to launch this first 
prospective study of feasibility, efficacy and safety of RSO in ar-
thritis of AC-joint.
The aim of our study was to prospectively assess the efficacy 
and safety of RSO of AC-joint using erbium-169 citrate.
Material and methods
The inclusion criteria for performing RSO using 169Er-citrate 
were pain and clinically confirmed persistent arthritis of AC-joint 
during more than 6 months, failure of previous systemic treatment, 
availability of two-phase bone scintigraphy (BS) consisting of blood 
pool imaging (BPI) phase and bone phase less than 2 months prior 
RSO with increased tracer uptake in concerned AC joint observed 
on BPI phase. 
The underlying cause of aseptic arthritis of AC joint (e.g. rheu-
matoid arthritis vs. osteoarthritis) was not taken into consideration. 
The exclusion criteria for performing RSO using 169Er-citrate were 
persisting pain less than 6 months, negative finding on BPI phase 
of two phase bone scintigraphy, personal history of traumatism of 
concerned shoulder, pregnancy, breast feeding and age less than 
18 years. 
Prior RSO, all patients gave their written consent. 
The control two phase BS was performed 4–8 months after 
RSO.
The efficacy of procedure was subjectively reported by patients; 
the criterion for efficacy of RSO was relief of pain assessed prior 
RSO and during follow up at 6 months using a 10-step visual ana-
logue scale of pain (VAS) [9]. The VAS was divided into 10 steps, 
from a level of no-pain (scale 0) to most severe pain imaginable 
(scale 10). The pain was documented by nuclear medicine physi-
cian in conjunction with referring physician; a pain relief by more 
than 2 steps on the VAS lasting for 12 consecutive weeks was used 
as a criterion for response. The variation of VAS in percent before 
and after RSO was assessed. 
The global effect of RSO was ranked by patients in 4 subjec-
tive categories adapted according to Liepe et al. [10]: excellent 
response (no symptoms, score 1); good response (significant 
reduction of symptoms, score 2); moderate response (slight de-
crease, score 3); and bad response (no change or worsening, score 
4), of pain in treated joint 6 months after procedure.
To assess the variation of blood pool perfusion in treated 
joints, the efficacy of RSO was also evaluated by variation of 
target (AC-joint)/non-target (soft tissue) uptake ratio (T/NTR) of 
metylendiphosphonate-99mTc. For this assessment, the following 
approach was used: the average count rate was calculated in 
manually drawn circular region of interest (ROI) covering the area 
of increased tracer uptake in the area of AC joint (target) on anterior 
view of pre-RSO planar BPI (Figure 1A). The average count rate 
was also calculated in corresponding ROI (target) on anterior view 
of post-RSO planar BPI (target) (Figure 1E). The activity of back-
ground (non-target) was calculated as the average count rate in 
manually drawn elliptic ROI on anterior view of pre- and post-RSO 
planar BPI (Figure 1A, E), covering approximately middle third of 
soft tissue of left femur excluding the large vessel area. 
The T/NTR and the variation of T/NTR in percent on pre- and 
post-RSO BPI were subsequently calculated.
The statistical analysis was performed using software MedCalc 
v17.6. For determining a significant change in the VAS and in T/NTR, 
the non-parametric Wilcoxon’s test was used to compare unpaired 
or paired quantitative data, respectively. A probability level p < 0.05 
was considered significant.
RSO of AC-joint
Given the size of AC-joint (comparable with that of small 
joints of hand or feet), the 169Er-citrate was designed as an optimal 
radiopharmaceutical in this indication [11]. 
After fluoroscopic verification of needle position, 0.1 mL of 
contrast agent was intra-articularly administered of to confirm the 
intraarticular position of the needle (Figure 1C). 
Subsequently the activity of 37 MBq of 169Er-citrate (CIS bio 
International, Gif-Sur-Yvette, France) in a volume of 0.1 mL was ad-
ministered and the needle was flushed by 0.1 mL of triamicinolone 
(20 mg/mL) (Figure 1D). After procedure the puncture site was ste-
rilely covered and the shoulder was immobilised for 48 hours. It 
was recommended to not to overload the treated extremity during 
7–10 days following procedure.
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Figure 1. A case of 58-years old female patient with polyarthritis. Two-phase bone scintigraphy with 519 MBq of 99mTc-metylenbisphosphonate 
including blood pool imaging phase (A) and bone phase (B); Whole body anterior (left) and posterior (right) views confirmed increased blood pool 
and increased osteoblastic activity in both AC (more pronounced on the right side), both I. carpometacarpal joints and in metatarsophalangeal 
joints on both sides; prosthesis of right hip and right knee. The RSO of right AC joint was indicated. After intraarticular instillation of 0.1 mL of 
contrast agent to confirm optimal needle position (C) the syringe was changed and 169Er-citrate was administered into articular cavity (D). After 
next change of syringes, the needle was flushed by 0.1 mL of triamicinolone 20 mg/mL. Six months after RSO of right AC joint the patient reported 
decrease in VAS from 8 to 2 and global effect of treatment was ranked as excellent. Follow-up two-phase BS was performed 6 months after 
treatment: BPI phase (E) and bone phase (F); Whole body anterior (left) and posterior (right) views. For calculation of target/non target ratio, 
the circular region of interest was drawn in the area of increased tracer uptake in the area of AC joint (target) (A, E arrow) and elliptical region of 
interest (non-target, background) (A, E dashed arrow) covering approximately medial third of soft tissues of the left femur, avoiding area of large 
vessels was drawn, both on planar anterior view of BPI. On semiquantitative assessment of blood pool perfusion of AC joint prior and after RSO 
the target/non target ratio decreased from 1.39 to 1.14 (by 17%). Persistent osteoblastic activity in both acromioclavicular joints (B, F), still more 
pronounced on the right side
A B
E
D
F
C
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Table 1. Visual analogue scale of pain and variation of target/non-target ratio prior and after radiosynoviorthesis of acromioclavicular joint and 
subjective evaluation of radiosynoviorthesis of each treated acromioclavicular joint
Number of treated 
AC-joints
Overall 
 
1st RSO 2nd RSO 
of the same
3rd RSO  
of the same
4th  RSO 
of the same
  AC-joint AC-joint AC-joint
n = 85 n = 69 n = 12 n = 3 n = 1
VAS prior RSO Mean 6.4 Mean 6.6 Mean 5.8 Mean 6.3 8
Range 3–10 Range 3–10 Range 4–7 Range 5–7  
Median 6 Median 6 Median 6    
VAS after RSO Mean 3.4 Mean 3.2 Mean 3.5 Mean 3.7 6
Range 0–8 Range 0–8 Range 2–5 Range 3–5  
Median 3 Median 3 Median 3.5    
Variation of VAS Mean -3.1 Mean -3.2 Mean -2.3 Mean -2.7 -2
Range 0 to -9 Range 0 to -9 Range 0 to -4 Range -2 to -4  
Median -3 Median -3 Median -2 Median -2  
Variation of VAS in % Mean 47% Mean -50.3% Mean -39.5% Mean -42% Mean -25%
Range -50% to -100% Range -100% to 0% Range -67% to 0% Range -57% to -29% Median -25%
Median -43% Median -50% Median -40% Median -40%  
VAS prior vs. after RSO p < 0.0001 p < 0.0001 p < 0.0001 — —
Subjective evaluation 1-4 Mean 3.6 Mean 3.7 Mean 3.4 Mean 3.7 Mean 3
Median 4 Median 4 Median 4 Median 4 Median 3
T/NTR prior RSO Mean 1.17 Mean 1.17 Mean 1.09 Mean 1.35 Mean 1.86
Range 0.21–2.6 Range 0.21–2.6 Range 0.24–2.5 Range 0.54–2.6 Median 1.86
Median 1.03 Median 1.15 Median 0.89 Median 0.9  
T/NTR after RSO Mean 1.03 Mean 1.04 Mean 0.99 Mean 1.01 Mean 1.69
Range 0.05–2.7 Range 0.05–2.7 Range 0.22–2.4 Range 0.47–1.95 Median 1.69
Median 0.94 Median 0.95 Median 0.74 Median 0.62  
Variation of T/NTR prior 
vs. after RSO
Mean -11% Mean -11% Mean -4% Mean -23% Mean -9%
Range -91% to -81% Range -91% to -81% Range -78% to -61% Range  -30% to -14% Median -9%
Median -0.1 Median -12% Median -5% Median -25%  
T/NTR prior vs. after RSO p < 0.0001 p < 0.0001 p = 0.5 — —
AC joint — acromioclavicular joint; RSO — radiosynoviorthesis; T/NTR — target/non-target ratio;  VAS — visual analogue scale of pain; vs. — versus
Results
Between March 2008 and December 2014, the RSO of 
clinically confirmed arthritis of AC-joint was performed in 51 pa-
tients (18 males, 33 females) mean age 64.3 (range 43.8–82.6, 
median 63.6) years. 
Two-phase bone scintigraphy using 99mTc-metylenbisphospho-
nate including BPI and bone phase was performed in all patients.
A total of 85 AC-joints were treated: 69 AC-joints were treated 
once, 12 AC-joints were treated twice, 3 AC-joints were treated 
three times, and one AC-joint was treated four times. Both left and 
right AC-joints were treated in 18 patients. 
The therapeutic effect of RSO was assessed 6 months after 
the treatment.
Prior RSO, no significant difference between 10-step VAS level 
in patients referred for first or for repeated RSO of the same AC-joint 
was observed (p = 0.15). In patients in whom both AC-joints were 
treated there was no significant difference between VAS level for 
the left and right AC-joint (p = 0.84).
The criterion for efficacy of RSO was pain relief assessed in 
a 10-step VAS during follow up at 6 months after RSO, the decrease 
by more than 2 steps being considered as therapeutic response. 
The results are summarised in Table 1. 
Overall, the RSO led to a significant decrease in VAS. Mean 
VAS prior RSO was 6.5 (range 3–10, median 6) vs. 3.4 (range 0–8, 
median 3) after treatment (p < 0.0001). The response to RSO 
was significantly more pronounced in patients referred for first RSO 
(n = 69) than in repeated RSO of the same articulation (n = 16); 
mean variation of VAS in patients referred for one single RSO 
was -3.2 (-50%) vs. -2.3 (-39%) in patients referred for repeated 
RSO (p = 0.02 (0.049)).
The interval between two consecutive RSO was mean 7 (range 
4.6–14.5, median 6) months. 
The global subjective effect of RSO was assessed by patients in 
4-grade scale. Excellent response or no symptoms of pain (score 1) 
was observed in 57 (67%) (48 first and 9 repeated RSO), good 
response or significant reduction of symptoms of pain (score 2) 
in 25 (19 first and 6 repeated RSO) (29%), moderate response 
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or slight decrease of pain (score 3) in 1 (first RSO) (1%) and bad 
response or no change or worsening of pain (score 4) in 2 (1 first 
and 1 repeated RSO) (2%) of treated AC-joints.
No significant difference in subjective evaluation of effect in 
case of first or repeated RSO was observed.
The score of subjective effect of RSO was significantly corre-
lated with variation of pain measured in 10-step VAS (ρ = 0.487 in 
case of first and ρ = 0.478 in case of repeated RSO, p < 0.001).
The target to background ratio (T/NTR) measured on BPI of 
the two-phase bone scintigraphy decreased by mean -11% (range 
-91% to +81%, median -10%).
A significant correlation between decrease of T/NTR and varia-
tion of VAS in % (ρ = 0.532, p < 0.0001) and between T/NTR and 
subjective evaluation of therapeutic effect in scale 1–4 (ρ = 0.388, 
p = 0.0002) was observed. However, it was not possible to identify 
the cut-off value of relative decrease in T/NTR permitting to detect 
the therapeutic response with sufficient sensitivity and specificity. 
The RSO of AC-joint(s) was perfectly tolerated by all patients. 
No complications, side effects or adverse reactions were observed.
Discussion
To the best of our knowledge, this is the first study of efficacy 
and safety of RSO to reduce inflammatory pain of AC-joint in 
a series of patients. 
In the context of lack of standard of truth to objectively determine 
the therapeutic response to RSO, similarly to other studies, the sub-
jective parameters had to be proposed including the VAS to observe 
the pain [9, 10] or ranking method subdividing the therapeutic effect 
in excellent, good, moderate, and bad response [10, 12]. Consid-
ering the decrease in VAS by more than 2 as a criterion for RSO 
efficacy, the response rate at 6 months in our series of patients in 
whom previous line(s) of treatment have failed was 47/85 (55%). 
The global evaluation of the effect of RSO by patients was excellent 
or good (score 1–2) by 82 (97%) of patients. 
In arthritis of small articulations of hand and feet treated by 
169Er-citrate, the pooled patient´s global evaluation of the effect of 
RSO using 169Er-citrate was excellent or good in 187/344 (54%) in 
the study of Liepe [10] vs. 82 (97%) of patients in our study, sug-
gesting also eventual differences in subjective perception of pain 
concerning different joints (e.g. pain of small articulations of hand 
and feet vs. pain of AC-joint). 
Increased articular blood pool perfusion in patients with 
rheumatologic conditions is indicative of active inflammation and 
has been suggested as a strong predictor of response to RSO [13]. 
In patients with rheumatoid arthritis and osteoarthritis, the clinical 
and scintigraphic outcomes were observed mainly in joints with 
decreasing blood pool indices and the response to RSO accord-
ing to BPI was associated with subjective response in 129/157 
(82.2 %) in the study of Zuderman et al. [13], underlining the BS 
as a valuable tool for monitoring RSO efficacy [8, 13]. In our study 
the two-phase BS including BPI and bone phase was performed 
less than 2 months prior and 4–8 months after RSO. The T/NTR 
decreased by mean -11% (range -91% to +81%, median -10%); 
a significant correlation between decrease of T/NTR and variation 
of VAS in % as well as between T/NTR and subjective evaluation 
of therapeutic effect in scale 1–4 was observed (p < 0.05); how-
ever, similarly as in other studies, it was not possible to identify the 
cut-off value of T/NTR variation permitting to identify a therapeutic 
response with sufficient sensitivity and specificity. 
In our series, a corticosteroid was administered during RSO. 
Using the similar approach the RSO of small articulations of hand 
resulted in good therapeutic effect in 25/36 (69%) of patients at 
6 months [14] and 128/154 (83%) of patients at 12 months [14, 15] 
vs. 131/157 (83%) of patients at 6 months [12, 16, 17] and 135/186 
(73%) of patients at 12 months [12, 16, 18] when RSO was per-
formed using 169Er-citrate alone, suggesting from pooled data 
of therapeutic effect at 12 months a significantly more frequent 
response to 169Er-citrate+corticosteroid than to 169Er-citrate alone 
(p = 0.019).
In case of persistent symptoms, repeated RSO can be repeated 
after 6 months; two failed RSOs should not be followed by subse-
quent administration of radionucliude [5]. 
Intraarticular treatment of persistent arthritis of AC joint by local 
instillation of corticosteroids is not a part of routine practice; there-
fore our data on efficacy of RSO of AC joint cannot be compared 
with systematic data on efficacy of local intraarticular treatment by 
corticosteroids.
In our series, after careful consideration, the RSO of the same 
AC-joint was performed more than twice in four patients: in 3 
patients three times and in 1 patient four times. In all cases the 
repeated RSO was performed within 6–14.5 months; the variation 
in VAS six months after each respective procedure was -2 in three 
cases and -4 in one case. The repeated procedure was perfectly 
tolerated in all cases; patients quoted the global efficacy of pro-
cedure as excellent response in two cases and good response in 
two cases and the T/NTR decreased by -9% to -25%.
From dosimetry point of view the intraarticular administration 
of 20–80 MBq of 169Er-citrate into trapeziometacarpal joint, in the 
absence of extra-articular diffusion leads to radiation dose of 
1820–7280, 660–2640, 260–1040 and 100–400 Gy at 0.1, 0.2, 
0.3 and 0.4 mm respectively. With intraarticular administration of 
80 MBq of 169Er-citrate and with an assumed accumulation of 
3% in the regional lymph nodes, radiation exposure in the lymph 
nodes can vary between 45.6 and 11.5 Gy for 1–4 accumulating 
lymph nodes. The whole body effective dose after intra-articular 
application of 20–80 MBq of 169Er-citrate is 1.65–6.6 mSv with an as-
sumed activity leakage from the joint of not more than 10% [11]. 
The maximal recommended activity of 169Er-citrate to be admin-
istered to one joint is 80 MBq (i.e. 160 MBq in case of two consecu-
tive administrations within interval of more than 6 months)  [11]. 
In our series, the constant activity of 37 MBq (corresponding to 
46% of maximal recommended activity) was administered at each 
RSO. Therefore, the total activity in patients receiving more than 
two RSOs of the same AC-joint ranged between 111 and 148 MBq 
corresponding to 69–93% of total cumulative recommended acti vity 
for two consecutive administrations. In the study of Manil et al. [19] 
the biological dosimetry of 169Er-citrate measured by scoring dicen-
trics in lymphocytes cultured from blood samples withdrawn just 
before and 6 hours, 24 hours and 7 days after RSO was negative 
in all 18 interpretable patients. 
It is debatable whether higher administered activities of 
169Er-citrate in RSO of AC-joint would lead to better therapeutic 
effect. No such data are currently available. 
Finally, RSO of AC-joint using 169Er-citrate is an affordable 
procedure. From our experience, the overall costs of RSO of one 
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AC-joint in are estimated on 180 €, including 130 € for 169Er-citrate 
and 50€ for disposable material. 
A limitation of present pilot study consist in impossibility of 
evaluation of therapeutic effect of RSO of AC joint according 
to underlying cause of arthritis (e.g. rheumatoid arthritis vs. os-
teoarthritis). However, in our heterogeneous series of patients not 
responding to previous treatments, the favourable results of RSO 
of AC joint encourage further evaluation of its efficacy according 
to underlying aetiology of aseptic arthritis. 
Conclusion
The results of this first prospective study of therapeutic 
effect of radiosynoviorthesis of acromioclavicular joint using 
169Er-citrate in a series of patients with clinically confirmed ar-
thritis of AC-joint permit to conclude the perfect tolerability in 
all patients and a good therapeutic efficacy in more than half 
patients in whom previous line(s) of treatment did not lead to 
satisfactory pain relief. 
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